

V. Wee Yong, brief bio:

Dr. V. Wee Yong is a Professor at the University of Calgary, Canada, and the Canada Research Chair in Neuroimmunology. He co-directs the Multiple Sclerosis (MS) NeuroTeam of the Hotchkiss Brain Institute at the University of Calgary, providing the basic science leadership, and he directs the provincial Alberta MS Network. Dr. Yong's research interests lie in the area of neuroimmunology, neuroprotection and CNS regeneration, and his projects are guided by MS, spinal cord injury and brain tumors. Dr. Yong has published 280 peer-reviewed manuscripts and his research has been translated into Phase III clinical trials in MS and spinal cord injury. His work has been cited over 17,500 times by other authors (web of science; h-index of 74). Dr. Yong is a past chair of the Medical Advisory Committee of the MS Society of Canada; this and other volunteer activities resulted in him receiving the Queen's Golden Jubilee Year Medallion. Dr. Yong is on the editorial board of 7 international journals. He has been the President of the International Society of Neuroimmunology (2014-2016). Dr. Yong is an elected fellow of both the Canadian Academy of Health Sciences and the Royal Society of Canada, which represent top honors for those working in the medical and academic sciences, respectively. Dr. Yong is the 2017 Allyn Taylor International Prize in Medicine winner.

Some publications the past 4 years:

1. Lau L, Cua R, Keough MB, Haylock-Jacob S, Yong VW, Pathophysiology of the brain extracellular matrix: A new target for remyelination, *Nature Rev Neuroscience* 14:722-729, 2013.
2. Stephenson E, Nathoo N, Mahjoub Y, Dunn JF, Yong VW, Iron in Multiple Sclerosis: Roles in neurodegeneration and repair, *Nature Rev Neurol* 10:459-468, 2014.
3. Keough MB, Rogers JA, Zhang P, Jensen SK, Robertson E, Chen T, Lau LW, Rawji KS, Plemel JR, Koch M, Ling CC, Yong VW, An inhibitor of chondroitin sulfate proteoglycan synthesis promotes CNS remyelination, *Nature Communications* 7:11312, 1-12, 2016.
4. Jensen SK, Yong VW, Activity-dependent and experience-driven myelination provide new directions for the management of multiple sclerosis, *Trends Neurosci* 39:356-365, 2016.
5. Clemente-Casares X, Blanco J, Ambalavalan P, Singha S, Yamanouchi J, Fandos C, Tsai S, Wang J, Agrawal S, Keough M, Yong VW, James E, Moore A, Yang Y, Stratmann T, Serra P, Santamaria P, Expanding antigen-specific regulatory networks to treat autoimmunity, *Nature* b530:434-440, 2016.
6. Mishra MK, Yong VW, Myeloid cells: targets of medications in multiple sclerosis, *Nature Rev Neurol* 12:539-551, 2016.
7. Metz LM, Li DKB, Traboulee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW for the Minocycline in

MS Study Team, Trial of minocycline in clinically isolated syndrome of multiple sclerosis, *New Engl J Med* 376:2122-2133, 2017.

8. Roger JA, Mishra MK, Hahn J, Greene C, Yates R, Metz L, Yong VW, Gestational BPA exposure lowers the threshold for autoimmunity in a model of multiple sclerosis, *Proc Natl Acad Sci (USA)* 114:4999-5004, 2017.
9. Plemel JR, Liu WQ, Yong VW, Remyelination therapies: a new direction and challenge in multiple sclerosis, *Nature Rev Drug Discovery* 16:617-634, 2017.

*More information about Dr. V. Wee Yong can be found at <https://www.ucalgary.ca/dcns/about-dcns/section-translational-neuroscience>.